[Test] Legionellosis Clinical Overview and Resources
Legionellosis
2020 Case Definition Legionnaires’ Disease, Pontiac Fever or Extrapulmonary Legionellosis
Clinical Criteria
Legionellosis is associated with three clinically and epidemiologically distinct illnesses: Legionnaires’ disease, Pontiac fever or extrapulmonary legionellosis.
Legionnaires’ disease: LD presents as pneumonia, diagnosed clinically and/or radiographically. Evidence of clinically compatible disease can be determined several ways: a) a clinical or radiographic diagnosis of pneumonia in the medical record or b) if “pneumonia” is not recorded explicitly, a description of clinical symptoms that are consistent with a diagnosis of pneumonia. Clinical symptoms of pneumonia may vary but must include acute onset of lower respiratory illness with fever and/or cough. Additional symptoms could include myalgia, shortness of breath, headache, malaise, chest discomfort, confusion, nausea, diarrhea or abdominal pain.
Pontiac fever: PF is a milder illness. While symptoms of PF could appear similar to those described for LD, there are distinguishing clinical features. PF does not present as pneumonia. It is less severe than LD, rarely requiring hospitalization. PF is self-limited, meaning it resolves without antibiotic treatment. Clinical symptoms may vary but must include acute symptom onset of one or more of the following: fever, chills, myalgia, malaise, headaches, fatigue, nausea and/or vomiting.
Extrapulmonary legionellosis: Legionella can cause disease at sites outside the lungs (for example, associated with endocarditis, wound infection, joint infection, graft infection). A diagnosis of extrapulmonary legionellosis is made when there is clinical evidence of disease at an extrapulmonary site and diagnostic testing indicates evidence of Legionella at that site.
Laboratory Criteria for Diagnosis
Confirmatory laboratory evidence:
- Isolation of any Legionella organism from lower respiratory secretions, lung tissue, pleural fluid or extrapulmonary site
- Detection of any Legionella species from lower respiratory secretions, lung tissue, pleural fluid or extrapulmonary site by a validated nucleic acid amplification test
- Detection of Legionella pneumophila serogroup 1 antigen in urine using validated reagents
- Fourfold or greater rise in specific serum antibody titer to Legionella pneumophila serogroup 1 using validated reagents
Supportive laboratory evidence:
- Fourfold or greater rise in antibody titer to specific species or serogroups of Legionella other than L. pneumophila serogroup 1 (e.g., L. micdadei, L. pneumophila serogroup 6)
- Fourfold or greater rise in antibody titer to multiple species of Legionella using pooled antigens.
- Detection of specific Legionella antigen or staining of the organism in lower respiratory secretions, lung tissue, pleural fluid or extrapulmonary site associated with clinical disease by direct fluorescent antibody staining, immunohistochemistry or other similar method, using validated reagents
Epidemiologic Linkage
Epidemiologic link to a setting with a confirmed source of Legionella (e.g., positive environmental sampling result associated with a cruise ship, public accommodation, cooling tower, etc.).
Or
- Epidemiologic link to a setting with a suspected source of Legionella that is associated with at least one confirmed case.
Criteria to Distinguish a New Case from an Existing Case
An individual should be considered a new case if their previous illness was followed by a period of recovery prior to acute onset of clinically compatible symptoms and subsequent laboratory evidence of infection. The recovery period for legionellosis can vary based on patient-specific factors. Centers for Disease Control consultation is encouraged for case classification of individuals without clear periods of recovery or subsequent acute illness onset.
Case Classification
Suspect:
- Suspect Legionnaires’ disease: A clinically compatible case of LD with supportive laboratory evidence for Legionella.
- Suspect Pontiac fever: A clinically compatible case of PF with supportive laboratory evidence for Legionella.
- Suspect Extrapulmonary legionellosis: A clinically compatible case of XPL with supportive laboratory evidence of Legionella at an extrapulmonary site.
Probable:
- Probable Legionnaires’ disease: A clinically compatible case with an epidemiologic link during the 14 days before onset of symptoms.
- Probable Pontiac fever: A clinically compatible case with an epidemiologic link during the three days before onset of symptoms.
Confirmed:
- Confirmed Legionnaires’ disease: A clinically compatible case of LD with confirmatory laboratory evidence for Legionella.
- Confirmed Pontiac fever: A clinically compatible case of PF with confirmatory laboratory evidence for Legionella.
- Confirmed extrapulmonary legionellosis: A clinically compatible case of XPL with confirmatory laboratory evidence of Legionella at an extrapulmonary site.
Prevention and Response Toolkit
Legionellosis Investigation Overview
The following guidelines provide a brief overview of the steps of a Legionellosis investigation.
Forms for Health Departments
Basic Steps of a Legionellosis Investigation
Know the disease/condition
- Read about Legionellosis in the CD Manual.
- See the case definition for Legionellosis in the CD Manual.
- Study APHA “Control of Communicable Diseases Manual,” 20th ed., pp 334‒337.
- Print and review reporting forms:
Part 1: Confidential Disease Report (DHHS 2124)
Part 2: Legionellosis (DHHS/EPI #18)
Collect clinical information
- If patient hospitalized for this disease, obtain medical record (admission note, progress note, lab report(s) and discharge summary).
- Obtain health care provider clinical notes from date(s) of service for this disease/condition.
- Look for evidence in the medical record that supports clinical findings described in the case definition.
- Look for evidence of immunosuppressive conditions or medications which would suppress the immune system; other predisposing conditions such as diabetes, malignancy, liver disease, kidney disease and especially chronic lung disease. Smokers should be considered as having chronic lung disease.
- Identify the date of illness onset, which may differ from the date of positive laboratory result
Review laboratory information
- Review laboratory report(s) specific to this disease.
- Evaluate laboratory results to determine if requirements of the case definition are satisfied.
Apply the case definition
- Use the case definition to determine if the clinical and laboratory findings meet the case definition criteria.
Attempt to identify source of exposure
- Review clinical documentation and interview patient or other knowledgeable person regarding potential exposures, including travel, health care and other potential sources, during the 10 days before illness onset:
- sources of aerosolized water (cooling towers, whirlpools, spas, pools, fountains, outdoor misters, humidifiers, nebulizers, C-PAP machines or other respiratory therapy devices)
- contact to moist soils (including peat moss and potting soils)
- recent outpatient medical care (e.g., physician offices, dental offices, dialysis centers, ambulatory surgery centers, etc.) recent inpatient medical care (e.g., hospitalizations, long-term care facilities
Implement control measures to prevent disease and additional exposures
- Use the CDC website to teach at-risk people about the disease.
- CD nurses should work with their environmental health specialist and other public health partners to evaluate the environmental risk, identify contaminated aerosolized water sources and assure disinfection.
Report to Communicable Disease Branch
- Enter Part 1 and Part 2 Communicable Disease Reports into NC EDSS as a new event or update the existing event if already entered.
- Assign event to State Disease Registrar when case investigation is complete.
Case finding
- During the course of the investigation, interview other exposed individuals for symptoms of illness.
- Refer symptomatic individuals to health care provider for evaluation.
State Laboratory of Public Health testing
- If microbiologic testing has not yet been performed and a respiratory specimen (e.g., sputum, lung tissue, pleural fluid) is available, consult with the CD Branch (919-733-3419) to determine if the specimen should be sent to the SLPH for microbiologic testing.
Risk communication
- Consider using risk communication tools conservatively if this is a low-profile case.
- Outbreaks might require North Carolina Health Alert Network alerts, EPI-X reports, MD alerts, and/or a press release. Consult with the CD Branch (919-733-3419) for guidance and assistance.
- DHHS Public Information Office (919-733-9190) is available to assist local health departments as needed.
Notes about the Disease
Although there are at least 39 species of Legionella bacteria, the best-known and most common causative agent for pneumonia (the most common clinical presentation) is L. pneumophila. In 1976, it took a bit of epidemiologic and microbiologic sleuthing to identify this “new” organism as the cause of an outbreak of pneumonia (“Legionnaires’ disease”) at an American Legion convention at a Philadelphia, Pa., hotel.
A number of LD outbreaks were identified retrospectively after the 1976 investigation. Legionellosis takes two clinical forms: acute bacterial pneumonia, often accompanied by abdominal pain and diarrhea (LD), and Pontiac fever. The latter, named for a 1968 outbreak originating in the Pontiac, Mich., health department, is a self-limited influenza-like illness that may actually be an immunologic response to inhaled bacterial antigen instead of an actual infection.
Pontiac fever has only been recognized in outbreak situations. In contrast, more often than not, LD occurs as sporadic individual cases, although, even in North Carolina, outbreaks continue to occur.1 NC has a link to the history of legionellosis in that the first retrospectively confirmed case of LD occurred at Fort Bragg during the summer of 1943.†
Legionella organisms are fairly common contaminants of aqueous environments, particularly in concert with free-living amoebae. Most outbreaks can be traced to aerosol exposure via air conditioner cooling towers, hot water systems (e.g., showers), misting devices, etc. However, some evidence exists to suggest dust or other soil exposure as a source. Those most susceptible to LD include smokers, the immunocompromised, the elderly and those with chronic lung disease.
Preventing LD devolves upon protecting the public against exposure to contaminated aerosols by, for example, properly maintaining cooling towers and safeguarding hot water systems in health care facilities where immunocompromised patients reside.
† There is confusion confusion in the medical literature (including the “Control of Communicable Diseases Manual”) about this date. Hugh Tatlock was a young U.S. Army medical officer stationed at Fort Bragg in the early 1940s. In 1944, he investigated an outbreak of “pretibial fever” (also called “Fort Bragg fever”), having worked on a separate respiratory illness cluster there the previous summer. He isolated different infectious agents from patients in each of these outbreaks. After years of work in different laboratories and some human experimentation, the pretibial fever agent was shown to be Leptospira interrogans, serovar autumnalis. The other “Tatlock agent,” initially described by Dr. Tatlock as “rickettsial-like,” also underwent a convoluted series of studies and eventually was identified as Legionella micdadei.2
- 1
J. Engel, “Water, Water, Everywhere! Legionnaires’ disease in NC,” Epi Notes 2006-1 (2006): 67, 9, www.epi.state.nc.us/epi/pdf/en2006-1.pdf.
- 2
WS Jordan Jr. “Section 1: Commission on Acute Respiratory Diseases,” The Armed Forces Epidemiological Board: The Histories of the Commissions, ed. TE Woodward (1994): 79-83, http://history.amedd.army.mil/booksdocs/historiesofcomsn/section1.htm.
This page was last modified on 11/09/2026